Magazine Article | May 9, 2017

Compassionate Use: The Family & Patient's Perspective

By Julie Deardorff, Ph.D., MPH, Contributing Editor

“The one thing I wish could have been different with the compassionate use program is that I would have known about it earlier,” says Nicole Pierson. Nicole’s son Gavin, who was diagnosed with a rare brain tumor when he was 5 years old, is alive today because he received IBRANCE (palbociclib) via compassionate use from Pfizer. Although IBRANCE didn’t cure him, it did prolong his life long enough until a new type of laser technology became available which ablated his tumor.

THIS CONTENT IS EXCLUSIVELY FOR LIFE SCIENCE LEADER PAID SUBSCRIBERS.
To continue reading this story and receive uninterrupted access to LSL Online and its monthly magazine subscribe to Life Science Leader today!
Already a subscriber? Log in now.